Medicago Inc. was a Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as bioreactors to produce proteins, candidate vaccines, and medications.

By using live plant leaves as hosts in the discovery and manufacturing process, the Medicago "Proficia" technology intended to create a rapid, high-yield system for its product candidates.

[12] In December 2021, the company announced that its CoVLP vaccine candidate exhibited 71% efficacy and no adverse effects in a multinational, Phase III clinical trial.

[18] Medicago used its proprietary Proficia technology, which is a possible alternative to traditional egg-based methods for producing virus-like particles (VLPs) used to manufacture vaccine candidates.

[18] The steps of the technology are: VLPs serve as potential vaccines by mimicking the natural structure and function of viruses, enabling recognition by the immune system.

[21] As of August 2020, the Medicago vaccine candidate was being evaluated for safety, toxicity, and immune response in a Phase I clinical trial at two locations in Quebec.

[11][23] As of January 2021, the Phase III trial was enrolling participants toward the total goal of 30,612, with each volunteer receiving two injections 21 days apart in an amount of 3.75 micrograms of CoVLP each time.

[13] In February 2022, Medicago and GlaxoSmithKline received authorization for CoVLP from Health Canada as an approved vaccine for preventing COVID-19 infection in adults 18 to 64 years old.